Sign up
Pharma Capital

Cynata Therapeutics meets with New York investors following good news from its stem cell candidate

Cynata Therapeutics Ltd (ASX:CYP) (OTCMKTS:CYYNF) CEO Ross Macdonald tells Proactive's Christine Corrado the cell therapy company has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product candidate in people with steroid-resistant acute graft-versus-host disease (GvHD).

Macdonald is in New York to present at the 20th Annual Rodman & Renshaw Global Investment Conference. Macdonald says Cynata's recent clinical data has "opened a lot of doors" to institutional investors, plus he says having a corporate partner in FUJIFILM (TYO:4901) helps to validate the technology.


View full CYP profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.